Keros Therapeutics, Inc.

The momentum for this stock is not very good. Keros Therapeutics, Inc. is not a good value stock. Keros Therapeutics, Inc. is not a good growth stock. Keros Therapeutics, Inc. is not very popular among insiders. Keros Therapeutics, Inc. is a mediocre stock to choose.

News

Keros Therapeutics price target lowered by $5 at BofA, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Buy" by Brokerages

Zolmax Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are presently covering the stock, MarketBeat reports...\n more…

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Buy" from Analysts

Ticker Report Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned an average recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat reports...\n more…

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Investor's Business Daily Keros Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 86.\nThe post Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark...\n more…

Keros Therapeutics (KROS) Receives a Buy from Truist Financial

TipRanks Financial Blog In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Keros Therapeutics (KROS - Research Report). The ...\n more…

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

Globe Newswire LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ( Keros or the Company ) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...\n more…